Ketamine for major depressive disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 31 Oct 2024: Trial registered, NCT06668571
  2. 10 Feb 2025: Trial started, NCT06668571

The trials

NCT01304147: Intranasal Ketamine in Treatment-Resistant Depression

State
Completed
Phase
No phase
People
20 taking part
Started
Oct 2011
Primary completion
Oct 2014
Arms
Ketamine
Results
Posted on the registry
  1. 25 Feb 2011: Trial registered
  2. 8 Feb 2017: Trial results posted

NCT06668571: Intravenous Ketamine for Treatment-Resistant Depression

State
Under way
Phase
Phase 2
People
30 planned
Started
10 Feb 2025
Primary completion
31 Dec 2027
Arms
Ketamine Group
Results
None posted
  1. 31 Oct 2024: Trial registered
  2. 10 Feb 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as 0.2 mg/kg ketamine, 1st perfusion of ketamine, 2nd perfusion of ketamine, Anaket v, Calypsol, CLORKETAM 1000, IMALGENE 1000, Intranasal Ketamine (IN), Intranasal ketamine, Ketafol component ketamine, KETASOL 100, Ketamine Infusion, Narketan, Tekam, Ursotamin, Vetaket.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.